Contact Information
  •   11190 Sunrise Valley Dr., Suite 300, Reston, VA, 20191
  •   stp@toxpath.org
  •   703-438-7508
open

STP Virtual Continuing Education Courses

Home / Meetings / Annual Meetings / STP Virtual Continuing Education Courses

The Society of Toxicologic Pathology offered three continuing education courses virtually in 2020. These programs were approved for 3.50 hours of continuing education credits per course in jurisdictions which recognize RACE approval. The course recordings are now available to registrants of the course(s) until November 30, 2020.

 

STP Virtual Continuing Education Courses with AAVSB RACE Approved for CE Credits logo seal

Vaccine Development from the Pathologist Perspective

Friday, August 28, 2020

Co-Chairs: Rani Sellers, DVM, PhD, DACVP, Pfizer Inc.; and Cynthia Rohde, PhD, Pfizer Inc.

The design and execution of toxicology studies supporting vaccine development have several unique elements relative to the conduct of traditional small molecule- or monoclonal antibody-supporting studies. This course is designed to give an overview of vaccine development, with emphasis on the regulatory guidances and special considerations in vaccine development (prophylactic and therapeutic), study design (including species selection), unique technical considerations, and anatomic and clinical pathology findings.

Introduction to Vaccine Developments, Cynthia M. Rohde, PhD, DABT, Pfizer Inc.
Animal Models to Support Vaccine Development, Rani Sellers, DVM, PhD, DACVP, Pfizer Inc.
Points to Consider in Vaccine Study Design and Implementation, Keith G. Nelson, DVM, PhD, DACVP, Charles River Laboratories
Anatomic and Clinical Pathology Interpretation and Correlations, Niraj K. Tripathi, BVSc, MVSc, PhD, DACVP, Covance
Anatomic and Clinical Pathology Interpretation and Correlations, Bindu Bennet, DVM, MSc, MS, PhD, Voyager Therapeutics
Coronaviruses and Vaccine Development, Rani Sellers, DVM, PhD, DACVP, Pfizer Inc.

View Recording & Access Materials  

Access is restricted to course registrants





Antibody Drug Conjugates (ADCs) as Cancer Therapies

Friday, September 11, 2020

Co-Chairs: William O. Iverson, DVM, Consultant; and Nancy E. Everds, DVM, DACVP, Seattle Genetics

Antibody-drug conjugates (ADCs), which use a specific antibody to deliver a toxic payload to target cells, hold great promise to increase efficacy and reduce adverse side effects, especially for oncology drugs. Six ADC molecules have received marketing approval in the US over the past 18 years. Nonclinical safety assessment has proven challenging as many ADCs still have steep dose-response curves and low therapeutic indices. Toxicities in many different organs and tissues have been seen, including bone marrow, skin, liver, kidney, eye, gastrointestinal tract, and nervous system. ADC-related toxicities may be more challenging to predict and manage than those seen with small molecules or unconjugated antibodies. This has led to more sophisticated engineering of antibodies, linkers, and drugs to increase internalization of drug by target cells, decrease off-target toxicity, and decrease bystander effects. This course will give an overview of synthesis and mechanisms of representative ADCs, and the clinical and anatomic pathology findings associated with different classes of agents, including immunomodulatory molecules and PROTACS.

Introduction, William O. Iverson, DVM, Consultant
Immune Modulatory Activity of Traditional and Nontraditional ADCs, Shyra J. Gardai, PhD, Seattle Genetics
Recent Progress in Antibody Drug Conjugates and PROTACs as New Modalities: Application to Oncology Drug Discovery, Lakshmaiah Gingipalli, PhD, AstraZeneca
Clinical Pathology Effects of Antibody Drug Conjugates in Toxicology Studies, Niraj K. Tripathi, BVSc, MVSc, PhD, DACVP, Covance
Anatomic Pathology Associated with Antibody Drug Conjugates, Matthew D. Smith, DVM, PhD, DACVP, Charles River Laboratories

View Recording & Access Materials  

Access is restricted to course registrants

The Safeguarding of Your Vital Organ Systems Depends on Safety Pharmacology: What Is It?

(Sponsored by the American College of Toxicology)

Friday, October 2, 2020

Co-Chairs: Michael K. Pugsley, MS, FBPhS, PhD, Cytokinetics; and Steve Tichenor, PhD, Charles River Laboratories

This continuing education course will include lectures that describe fundamental areas of safety pharmacology studies (CNS, Respiratory, Cardiovascular systems) for both new chemical entities (NCE) as well as biotechnology-derived products. It will also include some discussion of clinical issues (and methods) as well as novel non-clinical methods and approaches that may be added to the core ‘battery’ of tests used to explore the safety of novel therapeutic agents. Attendees will be introduced to discussion regarding the role safety pharmacology has as an integral component within the safety program for drug development. We will also introduce the Comprehensive In Vitro Proarrhythmia Assay (CIPA) cardiovascular paradigm being developed for hazard identification, elimination and risk assessment that would help to obviate conduct of the clinical “Through QT” (TQT) study. Furthermore, this course will provide attendees with a crucial resource that explains the important role safety pharmacology has in the overall pharmaceutical drug development process.

An Introduction to the Principles and Practice of Safety Pharmacology, Michael K. Pugsley, FBPhS, PhD, DSP, Cytokinetics
Core Battery 1: The Cardiovascular System, Michael K. Pugsley, FBPhS, PhD, DSP, Cytokinetics
Core Battery 2: The Central Nervous System, Susan M.G. Goody, PhD, Moderna Inc.
Core Battery 3: The Respiratory System, Steve Tichenor, PhD, Charles River Laboratories
A Safety Pharmacology Evaluation of Biopharmaceuticals, Michael J. Engwall, DVM, PhD, Amgen Inc.

View Recording & Access Materials  

Access is restricted to course registrants

  •  11190 Sunrise Valley Drive,
    Suite 300, Reston, VA 20191